| Cat. No. |
Product Name |
CAS No. |
Information |
| H9382 |
BMS587101
|
509083-77-6 |
BMS-587101 is a potent and orally active antagonist of leukocyte function associated antigen-1 (LFA-1). BMS-587101 has anti-inflammatory effects and can be used for rheumatoid arthritis research. |
| H9374 |
PF-06826647
|
2127109-84-4 |
PF-06826647(Ropsacitinib) is an orally active and selective TYK2 inhibitor (IC50=17 nM), which binds to TYK2 catalytically active JH1 domain. PF-06826647 displays selectivity for TYK2 over JAK1 (IC50=383 nM) and JAK2 (74 nM);PF-06826647 can be used for the research of psoriasis, ulcerative colitis, and hidradenitis suppurativa. |
| H9373 |
BMS-986202
|
1771691-34-9 |
BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 of 0.19 nM and a Ki of 0.02 nM; BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC50 of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. |
| H9360 |
BAY 1834845
|
1931994-80-7 |
BAY 1834845 is a potent and selective IRAK4 inhibitor with IC50 values of 3.4 nM respectively. |
| H9139 |
MP1032
|
350699-92-2 |
MP1032 is a novel anti-inflammatory drug that act as potent ROS scavengers; In a human Phase IIa trial, MP1032 demonstrated good clinical efficacy and safety in moderate psoriasis, highlighting the potential of redox-based therapies in chronic inflammatory and autoimmune diseases. |
| H8818 |
Deucravacitinib
|
1609392-27-9 |
BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. BMS-986165 inhibits IL-12/23 and type I IFN pathways. |
| H8769 |
Orismilast
|
1353546-86-7 |
Orismilast is a novel phosphodiesterase inhibitor. |
| H8087 |
BFH-772
|
890128-81-1 |
A potent, selective and orally active VEGFR2 tyrosine kinase inhibitor with IC50 of 3 nM; shows 40-fold less potent activity B-RAF, RET and TIE-2, and >500-fold for FLK-1, FLT-1 and FLT-4; inhibits ligand-induced autophosphorylation of RET, PDGFR and KIT with IC50 of 30-160 nM, potently inhibits VEGF-driven angiogenesis in a chamber model and rodent tumor models at daily doses of less than 3 mg/kg.
|
| H7080 |
Seletalisib
|
1362850-20-1 |
Seletalisib (UCB-5857) is a potent, ATP-competitive, and selective PI3Kδ inhibitor with IC50 of 12 nM; shows significant selectivity to PI3Kδ with respect to the other class I PI3K isoforms (204-303 fold); blocks AKT phosphorylation following activation of the B-cell receptor in a B-cell line; blocks human T-cell production of several cytokines from activated T-cells, and inhibits B-cell proliferation and cytokine release; dose-dependently inhibits anti-CD3-antibody-induced interleukin 2 release in mice.
|
| H6732 |
Tepilamide fumarate
|
1208229-58-6 |
A small-molecule, fumaric acid ester (FAE) compound that is a prodrug of methyl hydrogen fumarate (also known as monomethyl fumarate), for the treatment of relapsing-remitting multiple sclerosis and plaque psoriasis. |
$ USD
Select Your Country or Region
